Latest News

Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 2021

J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.

View article

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 2021

Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.

View article

What 20 years of clinical research has taught us about our industry and the future of drug development

June 2021

As Richmond Pharmacology approaches its 20th anniversary our co-founder and CEO reflects on the developments, regulatory changes, and innovations within the life science industry in an article in the PharmaTimes.

View article

Do we still need challenge trials with COVID-19?

April 2021

Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.

View article

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 2021

Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.

View article

A new era for UK-Japanese scientific relations

March 2021

Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad

View article

Low data variability

Exceptional ECG generation

Experts in cardiac safety

Our specialist services

News

Stay up to date with the latest activity at Richmond Pharmacology

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

What 20 years of clinical research has taught us about our industry and the future of drug development

Do we still need challenge trials with COVID-19?

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

A new era for UK-Japanese scientific relations

主要メンバー紹介

リッチモンドでのキャリア

動画紹介

Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme

Trial That Could Revolutionise Cardiac Safety Studies – Research Consortium Calls For Others To Join

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

私たちについて

ナレッジベース

ソーシャルメディア